Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson’s Disease by Yue Yin et al.
REVIEW ARTICLE
published: 29 May 2012
doi: 10.3389/fphys.2012.00171
Modulation of neuronal survival factor MEF2 by kinases in
Parkinson’s disease
YueYin1,2,3, Hua She2,3,Wenming Li 2,3, QianYang2,3, Shuzhong Guo1 and Zixu Mao2,3*
1 Institute of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China
2 Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA
3 Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
Edited by:
Matteo Barberis, Humboldt University
Berlin, Germany; Max Planck Institute
for Molecular Genetics, Berlin,
Germany
Reviewed by:
Noriko Hiroi, Keio University, Japan
Anatoly Sorokin, The Institute of Cell
Biophysics RAS, Russia
*Correspondence:
Zixu Mao, Departments of
Pharmacology and Neurology, Emory
University School of Medicine,
Whitehead Building, Room 565, 615
Michael Street, Atlanta, GA 30322,
USA.
e-mail: zmao@pharm.emory.edu
Parkinson’s disease (PD) is the second most common neurodegenerative disorder due
to selective death of neurons in the substantia nigra pars compacta. The cause of cell
death remains largely unknown. Myocyte enhancer factor 2 (MEF2) is a group of tran-
scriptional factors required to regulate neuronal development, synaptic plasticity, as well
as survival. Recent studies show that MEF2 functions are regulated in multiple subcellular
organelles and suggest that dysregulation of MEF2 plays essential roles in the patho-
genesis of PD. Many kinases associated with transcription, translation, protein misfolding,
autophagy, and cellular energy homeostasis are involved in the neurodegenerative process.
Following the first demonstration that mitogen-activated protein kinase p38 (p38 MAPK)
directly phosphorylates and activates MEF2 to promote neuronal survival, several other
kinase regulators of MEF2s have been identified.These include protein kinase A and extra-
cellular signal regulated kinase 5 as positive MEF2 regulators, and cyclin-dependent kinase
5 (Cdk5) and glycogen synthase kinase 3β as negative regulators in response to diverse
toxic signals relevant to PD. It is clear that MEF2 has emerged as a key point where survival
and death signals converge to exert their regulatory effects, and dysregulation of MEF2
function in multiple subcellular organelles may underlie PD pathogenesis. Moreover, sev-
eral other kinases such as leucine-rich repeat kinase 2 and PTEN-induced putative kinase
1 (PINK1) are of particular interest due to their potential interaction with MEF2.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disorder after Alzheimer’s disease (AD). Clinically PD is
characterized by resting tremor, bradykinesia, rigidity, and balance
difficulty, mostly along with autonomic abnormalities, psychiatric
disturbance, cognitive impairment, and dementia. Pathologically,
it is clear that PD results from the massive death of dopaminer-
gic (DA) neurons in the substantia nigra pars compacta (SNpc)
region. However, the causes of such selective neuronal death in PD
remain unknown. Current PD medication and therapy treat only
symptoms and cannot prevent or delay neuronal death (Dauer
and Przedborski, 2003). Our very limited understanding of mech-
anisms by which neurodegeneration is triggered constitutes the
main obstacle for the development of effective therapeutics to
cure this devastating disease. In spite of this, several risk factors
associated with the disease have been identified. Like other neu-
rodegenerative diseases, aging is generally considered to be the
greatest risk factor for PD (Lees et al., 2009). Exposure to envi-
ronmental toxins, such as herbicides, pesticides, lead, manganese,
welding, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
cyanide, carbon disulfide, and toluene, may produce similar but
not identical clinical features (Tanner and Aston, 2000; Elbaz and
Moisan, 2008). It is also been reported that head injury, well-water
ingestion, rural living, middle-age obesity, and lack of exercise may
have association with PD (Elbaz and Tranchant, 2007; Thacker
et al., 2008). Recently, genetic studies have made great break-
through in etiology of PD, revealing several genes that are closely
linked to heritable PD, which accounts for about 10% PD cases
(Paisán-Ruíz et al., 2004; Valente et al., 2004; Zimprich et al., 2004;
Seki et al., 2011). How these different factors may function together
in triggering PD remains unclear. Some researchers contend that
aging induces a pre-parkinsonian state, and that during normal
aging the cellular mechanisms of dopamine neuron demise are
accelerated or exaggerated through a combination of genetic and
environmental factors (Collier et al., 2011).
Identified initially in muscle cells, myocyte enhancer factor
2 (MEF2) is a member of the MCM1-agamous-deficiens-serum
response factor (MADS) family of transcription factors (Yu et al.,
1992). There are four members of MEF2 genes, MEF2A-D.
Although MEF2 was originally discovered in muscle cells to pro-
mote the expression of many muscle specific genes, they were late
found to be expressed in other tissues and cell types. For example,
MEF2s have been shown to participate in immune cell response,
glucose metabolism in adipocytes, angiogenesis, liver fibrosis, as
well as many essential molecular events in CNS such as neuronal
development, synaptic plasticity, and survival (Leifer et al., 1993;
Mao et al., 1999). More importantly, the loss of MEF2D-mediated
neuronal survival has been shown to underlie the process of the
survival of DA neurons in models of PD (Gong et al., 2003;
Smith et al., 2006). More recent findings have revealed several
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novel molecular mechanisms by which MEF2D may underlie the
pathogenic process of PD (Yang et al., 2009; She et al., 2011).
As a critical survival protein, MEF2s are tightly regulated via
posttranslational modification. It is known that phosphorylation
by kinases is an important process through which the activity of
MEF2 is up- or down-regulated. Several kinases have been linked
to neuronal survival in part due to their modulation of MEF2 func-
tion. Following the report that lipopolysaccharide (LPS) increases
the transactivation activity of MEF2C through phosphorylation by
p38 MAPK in monocytic cells during infection (Han et al., 1997),
MEF2 has been found to be activated by p38 in neurons to pro-
mote neuronal survival (Mao et al., 1999). Other kinases including
protein kinase A (PKA), extracellular signal regulated kinase 5
(ERK5), Cdk5, and glycogen synthase kinase 3β (GSK3β), have
subsequently been identified as regulators of MEF2 in neurons
(Gong et al., 2003; Liu et al., 2003; Wang et al., 2005, 2009).
Recent advances have revealed several genes whose alternations
have been associated with familial PD. These include genes for
SNCA, UCHL1, GIGYF2, HtrA2, LRRK2, PARK2, DJ1, PINK1,
and ATP13A2 (Kim and Choi, 2010; Seki et al., 2011). Leucine-
rich repeat kinase 2 (LRRK2) and PINK1 are of particular interest
because they are kinases and known to be involved in autophagy
and mitophagy, two processes to which MEF2D have been linked
(Paisán-Ruíz et al., 2004; Valente et al., 2004; Zimprich et al., 2004).
This raises the possibility that these two kinases may modulate
MEF2 function directly or indirectly in neurons.
THE POSITIVE MEF2 REGULATORS: p38, PKA, ERK5, AND
mTOR
p38: PHOSPHORYLATION OF MEF2 BY p38
p38 MAPK, which includes four different but functionally over-
lapping isoforms (p38α, p38β, p38γ, and p38δ), is a class of MAPK
family that is responsible to stress stimuli and involved in cell dif-
ferentiation and apoptosis (Han et al., 1994; Li et al., 1996; Mertens
et al., 1996; Jiang et al., 1997). p38 was first identified in stud-
ies of endotoxin-induced cell activation, which showed that p38
was tyrosine phosphorylated after extracellular changes in osmo-
larity in response to LPS (Han et al., 1993, 1994). p38 can be
activated by diverse extra/intracellular stimuli and various cellu-
lar stressors (Raingeaud et al., 1995; Xia et al., 1995; Graves et al.,
1996). In SH-SY5Y cells, rotenone-induced cell death requires the
activation of p38 while expression of dominant interfering form
of p38 attenuates rotenone-induced apoptosis (Newhouse et al.,
2004).
In response to physical-chemical stresses and proinflammatory
cytokines, p38 specifically phosphorylates Ser 387, Thr 293, and
Thr 300 within the MEF2C transactivation domain (Raingeaud
et al., 1995; Han et al., 1997). Similarly, it has been demonstrated
that under stimulation by UV light or interleukin-1 (IL-1), MEF2A
can also be phosphorylated by p38 at several key regulatory sites
such as Ser 383, Thr 312, and Thr 319, leading to enhanced tran-
scriptional activity of MEF2A (Yang et al., 1999; Zhao et al., 1999).
One study reported that MEF2D is not phosphorylated by p38 as
a substrate (Zhao et al., 1999). Since MEF2D can dimerize with
MEF2A, it was proposed that phosphorylation of MEF2A by p38
in the MEF2A and MEF2D complex may potentially up-regulate
MEF2-dependent gene expression (Zhao et al., 1999). However,
Rampalli et al. (2007) found that the phosphorylation of MEF2D
requires p38 signaling pathway and inhibition of p38 markedly
reduces MEF2D activity and target genes in mouse myoblast cells.
After the initial description that LPS regulated MEF2 via p38,
several studies started to focus on the role of p38-MEF2 in neurons.
Calcium functions as a second messenger mediating a wide range
of cellular responses in neurons (Ghosh and Greenberg, 1995). It
was shown that calcium influx into cerebellar neurons triggered
by extracellular stimuli induces activation of p38, leading to p38-
dependent and direct phosphorylation of MEF2C at Ser 387 (Han
et al., 1997; Mao et al., 1999). These findings, taken together, sug-
gest that calcium influx into neurons results in activation of the
MKK6-p38 cascade and phosphorylation and activation of MEF2
by p38.
Further studies showed that blocking the p38 signaling pathway
promotes apoptosis of differentiating neurons (Mao et al., 1999;
Okamoto et al., 2000). In cerebellar granule neurons (CGNs),
dominant-negative interfering forms of p38 reduced neuronal via-
bility by inhibiting the activity of MEF2. Increasing MEF2 activity
by expressing a constitutively active form of MEF2 in neurons
attenuated neuronal death induced by dominant-interfering p38
(Mao et al., 1999). These observations indicate that MEF2 protects
neurons from apoptosis in a p38 pathway-dependent manner.
PKA: PHOSPHORYLATION OF MEF2 BY PKA
It is known that neurons which receive insufficient trophic sup-
port will undergo apoptotic death (Oppenheim, 1991). Rydel et
al. reported that cyclic AMP (cAMP) could replace nerve growth
factor (NGF), one of the neurotrophic factors, in promoting long-
term survival in cultured rat neonatal sympathetic and embryonic
sensory neurons (Rydel and Greene, 1988). cAMP-mediated neu-
ronal survival requires the activation of cAMP-dependent protein
kinase (Rydel and Greene, 1988). One such major downstream
effector for cAMP is PKA.
Cerebellar granule neurons cultured in the presence of a
high concentration of extracellular KCl (25–30 mM) can sur-
vive in the absence of serum or other additional growth factors
due to high concentration of KCl-induced membrane depolar-
ization while low concentration of KCl induces CGN apopto-
sis (Franklin and Johnson, 1992; D’Mello et al., 1993; Miller
et al., 1997). Our studies showed that in this model, cAMP-
PKA pathway enhances MEF2-dependent DNA binding and gene
expression and promotes membrane depolarization-induced neu-
ronal survival (Wang et al., 2005). Blocking PKA activity with
two widely used kinase inhibitors, H89, and myristoylated PKI,
causes a concentration- and time-dependent loss of neuronal
viability. Based on the results of luciferase reporter gene assay,
high MEF2 activity is associated with membrane depolarization-
dependent survival, whereas apoptosis induced by low concen-
tration of KCl correlates with decreased MEF2 function. More
importantly, PKA could directly phosphorylate MEF2C at Thr 20,
which enhanced MEF2 DNA binding activity (Wang et al., 2005).
Together, these findings indicate that in response to membrane
depolarization, cAMP-PKA pathway stimulates MEF2 activity by
direct phosphorylation to promote neuronal survival.
ERK5: PHOSPHORYLATION OF MEF2 BY ERK5
Over a decade ago, ERK5, also known as the big MAP kinase
1 (BMK1), was discovered as a new member of MAP kinase
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family (Lee et al., 1995; Zhou et al., 1995). Similar to the other
two ERK group members, ERK1 and ERK2, ERK5 has a TEY
dual-phosphorylation motif but it possesses an unusual large C
terminus and a unique loop-12 sequence which distinguish it
from ERK1/2 (Lee et al., 1995). ERK5 is activated exclusively by its
upstream activator MAPK/ERK kinase 5 (MEK5), which does not
phosphorylate ERK1/2, c-Jun N-terminal protein kinase (JNK),
or p38 (English et al., 1995; Zhou et al., 1995). Subsequent studies
showed that the MEK5/ERK5 signaling pathway is involved in cell
survival, anti-apoptotic signaling, angiogenesis, cell motility, dif-
ferentiation, and cell proliferation (Liu et al., 2003; Hayashi et al.,
2005; Roberts et al., 2009).
As an important kinase activating numerous substrates, ERK5
has been found to phosphorylate a number of downstream tar-
gets including MEF2 (Kato et al., 1997; English et al., 1998;
Yang et al., 1998; Marinissen et al., 1999). Previous work demon-
strated that ERK5 specifically phosphorylated MEF2C at Ser 387
in response to serum stimulation, which greatly enhances the
transactivation activity of MEF2C, leading to increased MEF2C-
dependent gene expression (Kato et al., 1997). In contrast to
p38, further studies indicated that ERK5 also phosphorylates
MEF2A and MEF2D. Interestingly, phosphorylation by ERK5
was shown to enhance the transcriptional activity of MEF2A
but did not appear to affect MEF2D activity (Yang et al.,
1998).
Extracellular signal regulated kinase 5 is widely expressed in
many cell lines and tissues including a high level in the brain (Liu
et al., 2003; Yan et al., 2003; Buschbeck and Ullrich, 2005). It has
been reported that ERK5 can be activated by epidermal growth fac-
tor, G protein-coupled receptors, and neurotrophins (NTs) which
include NGF, brain-derived neurotrophic factor (BDNF), NT3,
NT4/5, and NT6 (Segal and Greenberg, 1996; Kato et al., 1998;
Kamakura et al., 1999; Marinissen et al., 1999). MEF2C is a well-
established substrate of ERK5 in cortical neurons from postnatal
day 0 rats (Cavanaugh et al., 2001). Subsequent work has shown
that regulation of MEF2C by activated ERK5 under BDNF or NT
seems to be functionally relevant to the survival of developing cor-
tical neurons but not mature neurons (Liu et al., 2003; Shalizi et al.,
2003). In primary cortical neurons cultured from embryonic day
17 (E17) rats, ERK5 activity mediates the neuroprotective func-
tion of BDNF by phosphorylating and activating MEF2. Blocking
either ERK5 activity or MEF2 transcription significantly reduces
BDNF protection against trophic withdrawal in E17 neurons (Liu
et al., 2003).
Oxidative damage contributes to the neurodegenerative process
and plays a role in PD pathogenesis (Dexter et al., 1989; Alam et al.,
1997a,b; Pearce et al., 1997; Floor and Wetzel, 1998; Sherer et al.,
2003). Suzaki et al. (2002) firstly reported that oxidative stress
such as H2O2 leads to protective activation of ERK5 in PC12 cells,
leading to an enhancement of DNA binding activity of MEF2.
Attenuating this enhancement by the MEK1/2 inhibitors, U0126
and PD98059, which have been reported to inhibit MEK5 also
(Kamakura et al., 1999), significantly augments the H2O2-induced
cell death (Suzaki et al., 2002). These findings suggest that regu-
lation of MEF2 by ERK5 exerts anti-apoptotic function against
oxidative stress.
mTOR: A POTENTIAL REGULATOR OF MEF2
Mammalian target of rapamycin (mTOR), also known as FK506
binding protein 12-rapamycin associated protein 1 (FRAP1), is a
serine/threonine protein kinase belonging to the phosphatidyli-
nositol 3-kinase (PI3K)-kinase-related kinase (PIKK) superfamily
(Kunz et al., 1993; Brown et al., 1994; Chiu et al., 1994; Sabatini
et al., 1994; Chen et al., 1995; Domin and Waterfield, 1997). mTOR
functions as at least two complexes, mTORC1 and mTORC2,
which consist of mTOR and unique mTOR-interacting proteins,
playing important roles in signaling network of cells (Hara et al.,
2002; Kim et al., 2002; Fingar and Blenis, 2004; Jacinto et al.,
2004; Sarbassov et al., 2004, 2006; Hresko and Mueckler, 2005;
Zhou and Huang, 2010). Raptor, an mTORC1 protein, can bind
to p70S6K and eukaryotic initiation factor 4E-binding protein 1
(4EBP1), the two best-characterized mTOR downstream targets
(Hara et al., 2002; Kim et al., 2002; Zhou and Huang, 2010).
By sensing growth factor, mitogen, energy, and nutrient signals,
mTORC1 participates in regulation of cell growth, proliferation,
and survival (Fingar and Blenis, 2004; Chong et al., 2010; Zhou
and Huang, 2010). The activation pathway of mTORC2 is still
far from being clearly elucidated. However, it has been reported
that mTORC2 lies downstream of PI3K and Akt to modulate cell
survival in response to growth factor (Hay and Sonenberg, 2004;
Jacinto et al., 2004; Hresko and Mueckler, 2005; Sarbassov et al.,
2006; Chong et al., 2010; Zhou and Huang, 2010).
Mammalian target of rapamycin also plays a central role in the
crossroads of different pathways regulating macroautophagy, also
called mTOR-dependent autophagy (Pattingre et al., 2008). Recent
studies have showed that ischemic brain injury induces a decrease
in phospho-mTOR and phospho-p70S6, which contributes to
neuronal death (Koh,2008; Koh et al.,2008). Based on these results,
we then investigated the interaction between mTOR/p70S6K path-
way and MEF2D, and revealed the function of mTOR/p70S6K in
regulating ischemic or hypoxia-induced MEF2D autophagy and
neuronal death (Tian et al., unpublished data).
Mammalian target of rapamycin pathway has been shown to
regulate MEF2 in non-neuronal cells (Xu and Wu, 2000). mTOR
pathway plays a critical role in cellular autophagy (Jung et al.,
2010). Our recent work demonstrated that chaperone-mediated
autophagy (CMA) modulates neuronal survival machinery by reg-
ulating MEF2D in neurons. This regulation is sensitive to the level
of nutrients and to the levels of α-synuclein (Yang et al., 2009).
Together, these findings suggest that mTOR may directly regulate
MEF2 in neurons in response to stress.
THE NEGATIVE MEF2 REGULATORS: Cdk5 AND GSK3β
Cdk5: PHOSPHORYLATION-INDUCED DEGRADATION OF MEF2
Two decades ago, a new member of cyclin-dependent kinase (Cdk)
family, Cdk5, was discovered (Hellmich et al., 1992; Lew et al.,
1992; Meyerson et al., 1992). The amino acid sequence of Cdk5
has up to 60% homology to that of human Cdk2 and cell division
cycle kinase 2 (Cdc2; Hellmich et al., 1992). However, unlike other
Cdk family members whose expression and activity fall to barely
detectable levels at the end of cytogenetic period, Cdk5 is expressed
in postmitotic neurons and appears to be inactive in dividing cells
(Tsai et al., 1993; Grant et al., 2001). Cdk5 is activated by binding
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to its neural enriched activators, p35 and p39 (or their respec-
tive truncated forms, p25 and p29) or by phosphorylation (Lew
et al., 1994; Tsai et al., 1994; Tang et al., 1995; Sharma et al., 1999;
Zukerberg et al., 2000; Tanaka et al., 2001).
Cdk5 is regulated in neurons through extensive cross-talks with
many signaling pathways (Ohshima et al., 1996; Chae et al., 1997;
Smith et al., 2001; Fu et al., 2002; Zhu et al., 2011). Cdk5 is essen-
tial for a variety of neuronal functions and lack of Cdk5 function
is destructive to CNS (Ko et al., 2001; Smith et al., 2001; Tanaka
et al., 2001). In developing neurons, Cdk5 is critically involved
in neuronal development via regulating axonal growth and path
finding, neurite growth and/or spine morphogenesis, and neu-
ronal migration. In the mature CNS, Cdk5 regulates multiple steps
which are essential for synaptic plasticity, neurotransmitter syn-
thesis, synaptic vesicle exocytosis, vesicle fusion, and endocytosis
by phosphorylating a number of substrates (Zheng et al., 1998;
Lagace et al., 2008; Zhu et al., 2011). Although lack of Cdk5 activ-
ity is detrimental to neurons, pathological overactivation of Cdk5
is also toxic to neurons, causing neuronal apoptosis under vari-
ous pathological conditions (Ahuja et al., 1997; Zhang et al., 1997;
Patrick et al., 1999; Gao et al., 2001).
One important mechanism by which overactivated Cdk5 trig-
gers neuronal death is to inhibit the function of neuroprotective
factor MEF2 (Gong et al., 2003). We first illustrated that Cdk5/p35
kinase complex regulated MEF2 by phosphorylating MEF2 at Ser
408a/444d (Ser 408 of MEF2A and Ser 444 of MEF2D) in neurons.
Elevated Cdk5 activity inhibited MEF2 transactivation activity in
cortical neurons and co-expression of Cdk5 and p25 led to even
greater inhibition.
Neurotoxic insults including oxidative stress and excitotoxic-
ity cause neuronal death and are widely believed to play a role in
neurodegenerative processes including PD. Our analysis showed
that in either cortical or CGNs, oxidative, and excitotoxic stresses
markedly increase the kinase activity of Cdk5 in the nucleus.
This is followed with a decline of MEF2D activity. Nuclear Cdk5
directly phosphorylates MEF2D at Ser 444. Phosphorylation of
MEF2D at Ser 444 led clearly to destabilization of MEF2D and
its activity (Gong et al., 2003). Inhibiting Cdk5 with roscovi-
tine significantly blocked the phosphorylation of MEF2D at Ser
444 and rescued cortical and CGNs from excitotoxicity-induced
deaths.
Our subsequent work revealed a novel mechanism by which
phosphorylation of MEF2D by Cdk5 inhibits its activity. Exci-
totoxicity activates caspases in neurons. We demonstrated that
phosphorylation of MEF2D by Cdk5 makes MEF2D a very
good substrate for caspases, and its degradation by caspases
(Tang et al., 2005). This degradation correlated with increased
neuronal apoptosis. Inhibition of Cdk5 by a small molecule
inhibitor roscovitine or increasing a form of MEF2D which can-
not be phosphorylated by Cdk5 protected neurons from death,
indicating that caspase-mediated MEF2 degradation is a crit-
ical mechanism underlying excitotoxicity and oxidative stress.
In contrast to MEF2A and MEF2D, MEF2C is not phosphory-
lated by Cdk5 after glutamate exposure and, therefore, resistant
to neurotoxin-induced caspase-dependent degradation, suggest-
ing that such degradation is MEF2 isoform specific (Tang et al.,
2005).
GSK3β: DOWN-REGULATING MEF2D TRANSACTIVATION
In 1980, a glycogen synthase kinase was partially purified from
rabbit skeletal muscle and was named glycogen synthase kinase
3 (GSK3) to distinct from both cyclic-AMP-dependent protein
kinase and phosphorylase (Embi et al., 1980; Rylatt et al., 1980).
Sequence analysis revealed two gsk3 genes, encoding two isoforms
termed GSK3α and GSK3β (Woodgett, 1990). GSK3β has two
sites of phosphorylation, Ser 9 and Tyr 216, and phosphoryla-
tion at Ser 9 inhibits GSK3β activity while phosphorylation at
Tyr 216 enhances its activity (Hughes et al., 1993; Cross et al.,
1995). With its high level of expression in brain (Tung and Reed,
1989), GSK3βhas been shown to play a prominent role in neuronal
stress conditions such as in response to potassium deprivation and
trophic withdrawal. Overexpression of it leads to caspase activa-
tion, neuronal loss, and gliosis (Pap and Cooper, 1998; Hetman
et al., 2000; Lucas et al., 2001; Mora et al., 2001; Kaytor and
Orr, 2002). Aberrant GSK3β activity had been associated with PD
(Kwok et al., 2005; Kalinderi et al., 2011). However, the molecu-
lar mechanisms by which GSK3β mediates neuronal death require
further elucidation.
Potassium-induced membrane depolarization is a widely used
model of neuronal survival. In this model, potassium withdrawal
induces CGNs to undergo synchronized apoptosis. It has been
reported that in SH-SY5Y cells, GSK3β accumulates in the nuclei
after serum withdrawal and this accumulation occurs early in the
apoptotic process, preceding activation of caspases (Bijur and Jope,
2001). Based on these, we examined the regulation of MEF2D in
CGNs following potassium withdrawal by GSK3β (Wang et al.,
2009). Our analysis showed that potassium withdrawal causes
a decrease in GSK3β protein in the cytoplasm of CGNs but an
increase in the nuclei. This was accompanied by an elevation of
nuclear GSK3β activity as shown by decreased inhibitory phos-
phorylation at Ser 9 (Wang et al., 2009). In vitro, GSK3β directly
phosphorylated MEF2D. Mutation of amino acid residues Thr145,
Ser149, and Ser153 in combination led to a substantial attenuation
of MEF2D phosphorylation by GSK3β, suggesting that MEF2D is
a GSK3β substrate. High level nuclear GSK3β activity correlated
with a decline in MEF2 DNA binding and transcriptional activities.
Over time, this decline also correlated with a decline in the levels of
MEF2D protein (Wang et al., 2009). Blocking GSK3β activity by its
inhibitor LiCl or SB216763 remarkably restored MEF2D level and
activity, and prevented KCl-induced CGN death. Moreover, over-
expression of MEF2D T145A/S153A mutant, which was resistant
to GSK3β phosphorylation, also reduced the number of apoptotic
neurons during KCl deprivation. These findings suggest suggest-
ing that inhibition of MEF2D by GSK3β pathway plays an essential
role in mediating neuronal apoptosis caused by KCl withdrawal.
OTHER KINASES RELATED TO PD
LRRK2
One of the most important advances in PD research in the past
decade is the revelation of the genetic risk associated with PD,
which has altered the previous concept that this age-related disease
had little genetic component (Cookson, 2010). One of the genes
found to be highly associated with familial PD is LRRK2, which
encodes the protein leucine-rich repeat kinase 2 (Wider et al.,
2010). Despite the fact that the physiologic functions of LRRK2
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protein are still poorly understood in neurons, the genetic evidence
is clear that mutation of this gene causes familial PD (R1441C,
Y1699C, G2019S, R1441G, R1441H, and I2020T), accounting for
1% of sporadic PD and 4% of autosomal PD (Paisán-Ruíz et al.,
2004; Zimprich et al., 2004; Healy et al., 2008; Devine et al., 2011;
Drolet et al., 2011).
LRRK2 has been implicated in regulation of macroautophagy.
It was found that overexpression of G2019S mutant LRRK2 in
neuronal cells decreased neurite length and caused an accumula-
tion of autophagic structures (MacLeod et al., 2006; Plowey et al.,
2008; Ramonet et al., 2011). Similarly, overexpression of wild type
LRRK2 in non-neuronal and yeast cells also led to an imbalance of
macroautophagic process (Alegre-Abarrategui et al., 2009; Xiong
et al., 2010). More recently, a study reported that LRRK2 acti-
vates the calcium-dependent protein kinase kinase-β/adenosine
monophosphate-activated protein kinase (AMPK) to increase
macroautophagy (Gomez-Suaga et al., 2012). This appeared to
require the function of the lysosomal Ca2+-mobilizing messenger
nicotinic acid adenine dinucleotide phosphate (NAADP).
LRRK2 may also modulate autophagy by affecting α-synuclein,
encoded by one of the PD-related genes, SNCA. α-synuclein is
the main protein aggregated in Lewy Bodies, the intraneuronal
inclusions in surviving neurons and pathologic hallmark of PD
(Spillantini et al., 1997; Braak et al., 2003). It was reported that
after transgenic mice with mutant human LRRK2 are crossed
with mice over-expressing mutant human SNCA, accumulation
of α-synuclein is increased compared with mice over-expressing
SNCA alone (Lin et al., 2009). In addition, over-expressing LRRK2
has been reported to accelerate the progression of α-synuclein-
mediated neuropathology, promote the abnormal accumulation
of α-synuclein in cell bodies and the formation of α-synuclein
aggregates (Lin et al., 2009). Since α-synuclein is known to be
regulated by CMA as well as by macroautophagy (Williams et al.,
2006; Vogiatzi et al., 2008) and to modulate CMA-dependent regu-
lation of MEF2D in DA neurons (Yang et al., 2009), these findings
raise an intriguing possibility that LRRK2 may act upstream of
α-synuclein and modulate MEF2 which may underlie in part the
neurotoxicity caused by LRRK2 and play a role in the pathogenic
process of PD.
PINK1
When PTEN-induced putative kinase 1 (PINK1) was first identi-
fied, its abundant expression in heart, skeletal muscle, and testis
but not brain offered little clue that this kinase could be connected
to PD (Unoki and Nakamura, 2001). Soon after that, Valente et al.
(2004) discovered two mutations in PINK1 gene affecting PINK1
kinase activity, which abrogates its protective effect on cells and is
responsible for a form of heritable early onset PD. PINK1 localizes
to mitochondria. Its loss of activity offers a molecular link between
mitochondrial function and the pathogenesis of PD (Valente et al.,
2004).
Shortly after the discovery that Parkin, whose gene muta-
tion causes familial PD, can selectively promote the removal
of damaged mitochondria by autophagy (mitophagy; Narendra
et al., 2008), it was shown that PINK1 cooperatively regulate
mitophagy with Parkin (Geisler et al., 2010; Matsuda et al.,
2010; Narendra et al., 2010; Vives-Bauza et al., 2010). When
mitochondrial membrane potential decreases, PINK1 is stabi-
lized and accumulates selectively in dysfunctional mitochondria,
allowing it to retrieve Parkin from the cytoplasm to the mito-
chondria where Parkin initiates the degradation of damaged mito-
chondria (Matsuda et al., 2010; Narendra et al., 2010). As an
upstream effector, PINK1 is required by Parkin recruitment and
Parkin-induced mitophagy because reducing PINK1 by PINK1
siRNA significantly blocks Parkin recruitment and mitophagy,
suggesting that PINK1-Parkin pathway is a crucial mechanism
by which mitophagy is mediated (Narendra et al., 2010; Vives-
Bauza et al., 2010). This is relevant to PD since PINK1 muta-
tion linked to PD disrupts mitophagy and respiratory chain,
resulting in mitochondrial dysfunction and contributing to PD
(Amo et al., 2011; Sato and Hattori, 2011). MEF2D is regulated
by autophagy and has been shown to localize to mitochon-
dria and regulate mitochondrial gene transcription, complex I
activity of oxidative phosphorylation chain, and ATP produc-
tion (She et al., 2011). Whether PINK1 and MEF2D pathway
may cross-talk is an interesting open question and awaits further
investigation.
FUTURE PERSPECTIVES
As discussed above, newly identified genes associated with familial
forms of PD have provided powerful tools for us to delineate the
FIGURE 1 | Regulation of MEF2 by kinases in Parkinson’s disease.
MEF2 is a key point where survival and death signals converge to exert
their regulatory effects. p38, PKA, ERK5, and mTOR have been identified as
positive MEF2 regulators whereas Cdk5 and GSK3β are negative regulators
in response to diverse toxic signals relevant to PD.
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molecular links underlying the key pathogenic processes in the
disease. We have summarized some of the findings of key kinases
whose activities have been linked to MEF2D or PD (Figure 1).
Some of them are likely to form an interconnected regulatory
network which links together several key subcellular organelles
and processes already implicated in PD. They, therefore, provide
the basis for further investigation of the molecular basis of PD
pathogenesis and provide novel targets such as MEF2 for the
development of new therapeutic strategies.
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